SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Novo Nordisk A/S (NONOF) trades at a trailing P/E of 1.7, forward P/E of 1.9. Trailing earnings yield is 59.17%, forward earnings yield 53.19%. PEG 1.13.
Criteria proven by this page:
- VALUE (100/100, Pass) — P/E is below market average (1.7); earnings yield beats bond yields (59.17%).
- PEG Ratio 1.13 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 59.17% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income.
Overall SharesGrow Score: 87/100 with 6/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NONOF
Valuation Multiples
P/E (TTM)1.7
Forward P/E1.9
PEG Ratio1.13
Forward PEG0.24
P/B Ratio0.00
P/S Ratio0.56
EV/EBITDA0.0
Per Share Data
EPS (TTM)$22.98
Forward EPS (Est.)$20.68
Book Value / Share$0.00
Revenue / Share$69.33
FCF / Share$0.00
Yields & Fair Value
Earnings Yield59.17%
Forward Earnings Yield53.19%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$7.48 |
$111.78B |
$37.93B |
33.9% |
| 2017 |
$7.70 |
$111.7B |
$38.13B |
34.1% |
| 2018 |
$3.99 |
$111.83B |
$38.63B |
34.5% |
| 2019 |
$4.10 |
$122.02B |
$38.95B |
31.9% |
| 2020 |
$9.01 |
$126.95B |
$42.14B |
33.2% |
| 2021 |
$10.37 |
$140.8B |
$47.76B |
33.9% |
| 2022 |
$12.22 |
$176.95B |
$55.53B |
31.4% |
| 2023 |
$9.31 |
$232.26B |
$83.68B |
36% |
| 2024 |
$22.64 |
$290.4B |
$100.99B |
34.8% |
| 2025 |
$22.98 |
$308.36B |
$102.2B |
33.1% |
